test

February 2026

• Press release Feb 27, 2026
  Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
  Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with…
• Press release Feb 25, 2026
  Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
  Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands…
• 
  Story Feb 25, 2026 Discovery
  Breaking ground in Global Health
  Discovery
• Press release Feb 24, 2026
  New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
  In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI…
• Press release Feb 23, 2026
  Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
  Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut…
• Press release Feb 18, 2026
  Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
  Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-…
• Press release Feb 13, 2026
  Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
  In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple…
• 
  Story Feb 11, 2026
  Victor Bulto and Thierry Diagana named to 2026 TIME100 Health List
• 
  Story Feb 09, 2026 Discovery
  What's next in Neuroscience drug discovery
  Discovery
• Press release Feb 06, 2026
  Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
  New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,…
• Ad hoc release Feb 04, 2026
  Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
  Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from…
• Ad hoc release Feb 04, 2026
  Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
  Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf…